BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2019 4:33:37 AM | Browse: 1235 | Download: 2048
 |
Received |
|
2018-10-17 02:48 |
|
Peer-Review Started |
|
2018-10-17 08:52 |
|
First Decision by Editorial Office Director |
|
2018-11-27 19:43 |
|
Return for Revision |
|
2018-11-30 02:42 |
|
Revised |
|
2018-12-31 12:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-01-16 08:54 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-01-23 17:31 |
|
Articles in Press |
|
2019-01-23 17:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-02-21 09:34 |
|
Publish the Manuscript Online |
|
2019-02-22 04:33 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt and François Ghiringhelli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
François Ghiringhelli, MD, Attending Doctor, Doctor, Doctor, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr |
| Key Words |
Colorectal cancer; Chemotherapy; Irinotecan; Second-line; Aflibercept |
| Core Tip |
This retrospective study suggests that modified FOLFIRI with injection of irinotecan at day 1 and 3 is interesting for patients with previously treated metastatic colorectal cancer. Surprisingly the efficacy of the FOLFIRI3-aflibercept seems superior the FOLFIRI3 alone or in combination with bevacizumab. Prospective randomized trial comparing FOLFIRI-aflibercept to FOLFIRI3-aflibercept in second line are warranted. |
| Publish Date |
2019-02-22 04:33 |
| Citation |
Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i2.75 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
